CIBC World Market
BCRX icon

CIBC World Market’s BioCryst Pharmaceuticals BCRX Stock Holding History

CIBC World Market’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,500
Closed -$236K – 1279
2022
Q1 		$236K Hold
14,500
– – ﹤0.01% 1152
2021
Q4 		$201K Hold
14,500
– – ﹤0.01% 1253
2021
Q3 		$208K Buy
+14,500
New +$229K ﹤0.01% 1252

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC World Market's BCRX Position: Q2 2022 in Review

CIBC World Market sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 14,500 shares — an estimated $236K sold.

CIBC World Market first reported a position in BCRX in Q3 2021 and held it in 3 quarters. The position peaked at $236K in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • CIBC World Market reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • CIBC World Market sold 14,500 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $236K.
  • CIBC World Market first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • CIBC World Market's BioCryst Pharmaceuticals position peaked at $236K in Q1 2022.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on CIBC World Market's 13F filing for Q2 2022, filed 10 Aug 2022.